Brain tissue contains multiple forms of Phospholipase A 2 (PLA 2 ) whose activities are involved in intracellular and intercellular signalling related to normal functions such as long-term potentiation, neurotransmitter release, cell growth and differentiation. Among them, we focused on regulatory mechanism of cPLA 2 a (Group IVA cytosolic PLA 2 ) in brain tissue. In the present study, we report the identification of a cPLA 2 -activating protein (cPLAP) in the bovine brain. cPLAP activity appeared as two major peaks with molecular masses of 200 and 42 kDa in a Superose 12 gel filtration FPLC column. The 42-kDa form of cPLAP, designated cPLAPc, was further purified using a Mono S FPLC column to near homogeneity and characterized to as a GTP-binding protein (G protein). Metabolic labelling and immunoprecipitation studies revealed that cPLAPc associates with cPLA 2 in vitro and co-immunoprecipitates with [ 35 S]-cPLA 2 . Notably, cPLAPc rendered cPLA 2 fully activated at submicromolar concentrations of Ca 2þ . These results suggest that cPLAPc may act as a G protein, activating cPLA 2 a prior to reaching full intracellular Ca 2þ concentrations.
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Phospholipase A 2 (PLA 2 : EC 3.1.1.4) are ubiquitous enzymes that specifically hydrolyze the acyl ester bond at the sn-2 position of membrane phospholipids to produce a free acid and lysophospholipid (1) .
Brain tissue contains multiple forms of PLA 2 , whose activities are involved in intracellular and intercellular signalling related to normal functions such as long-term potentiation, neurotransmitter release, cell growth, and differentiation (2) . Increased levels or activity of PLA 2 and excessive production of arachidonic acid (AA) and lysophospholipids may lead to disease states and neuronal injury or neurodegenerative diseases (3), including Alzheimer's disease (4), multiple sclerosis (5), olivopontocerebellar atrophy (6) , as well as psychiatric disorders such as schizophrenia (7) .
Recent advances in molecular biology of PLA 2 have led to the identification of more than 20 isoforms with PLA 2 activity. The PLA 2 can be divided into several groups depending upon enzymatic properties, subcellular localization, their structure and cellular function (2) . These are secretory PLA 2 (sPLA 2 ), cytosolic PLA 2 (cPLA 2 ) and calcium-independent PLA 2 (iPLA 2 ). Among them, the most thoroughly investigated group of PLA 2 is cPLA 2 (Group IV PLA 2 ) in brain tissue. Our laboratory has focused on the study of the group IVA cPLA 2 (Group IVA PLA 2 or cPLA 2 a). Although brain tissue contains cPLA 2 activity, it has never been purified to homogeneity and characterized from brain (2). Thus, not only its regulatory mechanism of AA release in the brain but also the existence of cPLA 2 as an active enzyme in the brain remains largely uncertain.
Although to date extensive studies have focused on the regulatory mechanism of cPLA 2 , the precise mechanism remains not fully understood. At present, three major mechanisms have been elucidated. First, Ca 2þ is an important regulator of cPLA 2 activity. This enzyme has a Ca 2þ -dependent lipid-binding (CaLB) domain, which is responsible for translocation of cPLA 2 from the cytosol to the membrane compartment in the presence of 10 À6 M Ca 2þ (8, 9) . That is, cPLA 2 requires Ca 2þ only for translocation and association with its substrate membrane via the CaLB domain. Second, phosphorylation of cPLA 2 is also postulated as a possible mechanism of activation. Diverse agonists that provoke the release of AA also activate a variety of kinases (1012). Third, ceramide can interact directly with cPLA 2 via the CaLB domain and thereby serves as a membrane-docking device that facilitates cPLA 2 action in inflammatory diseases (13) . Moreover, ceramide-1-phosphate not only increases the membrane affinity of cPLA 2 but also may act as an allosteric activator of the membrane-associated enzyme (14) . However, detailed mechanisms of its regulation remain to be elucidated.
In a signal transduction concept first proposed by Rodbell et al. (15) , GTP-binding regulatory protein (G protein) was proposed as a transducer or a molecular switch. Many phospholipases have been found to interact with and be directly regulated by specific G proteins, e.g. phospholipase C (PLC) by heterotrimeric G proteins (16, 17) and phospholipase D by ADP-ribosylation factor (18) . In the brain, PLA 2 activity and AA release are linked to the receptors for dopamine, glutamate, serotonin, P2-purinergics, cytokines and growth factors through various coupling mechanisms (1923) . In the case of PLA 2 , there have been many trials to identify the corresponding G protein that regulates PLA 2 s, especially high-molecular weight cPLA 2 a, which is hormonally regulated (24) . Using the non-hydrolysable guanine nucleotide analogues GTPgS/GDPbS and G protein-sensitive bacterial toxins such as cholera toxin and pertussis toxin, there are an increasing number of reports suggesting that AA release in various cells and tissues is regulated by G proteins (25) . cPLA 2 is regulated by Ras-related C3 botulinum toxin substrate 1 (Rac1), a member of the Rho family of G proteins, which acts as a molecular switch by cycling between active GTP bound and inactive GDP-bound forms (26) . Rac1 binds to effector molecules in its GTP bound form, and influences cPLA 2 activation and subsequent release of AA (2729). However, at present, there is no evidence for direct interaction of cPLA 2 with a G protein either in vivo or in vitro.
On the other hand, 28-kDa PLA 2 -activating protein (PLAP) has been identified and characterized (30) . The PLAP stimulated sPLA 2 but not cPLA 2 . The purified protein selectively stimulated sPLA 2 when phosphatidylcholine (PC) was used as a substrate but had no effect on activity with phosphatidylethanolamine (PE) as a substrate. Interestingly, a homology search identified that PLAP has a domain exhibiting significant homology with b-transducin, a member of the G b superfamily. However, the importance of this domain for PLAP activity remains unknown, as PLAP activity has not been shown to be affected by GTPgS or GDPbS.
In the present study, we identified a cPLA 2 -activating protein (cPLAP) in the bovine brain that specifically enhanced the in vitro activity of porcine spleen cPLA 2 . The cPLAP activity appeared as two major peaks with molecular masses of 200 and 42 kDa on a Superose 12-gel filtration FPLC column. We also demonstrate here that a polyclonal antibody generated against the cPLA 2 a protein immunoprecipitated 42 kDa cPLAP (cPLAPg) from bovine brain as well as human promyelocytic leukaemia HL60 and human leukaemic monocyte lymphoma U937 cell lines in metabolic labelling study. These results strongly suggest that cPLAPg may be a G protein which fully activates cPLA 2 at sub-micromolar concentrations of Ca 2þ .
Materials and Methods
C]AA-GPE) (55.6 mCi/mol) and [a-32 P]GTP (1 mCi/ml, 3000 Ci/mmol) were purchased from Amersham Life Science, Ltd (Buckinghamshire, England). DEAE-cellulose gel (DE52) was purchased from Whatman Co (Maidstone, England) and Phenyl-Sepharose CL-4B gel, Resource S column and PD-10 were purchased from Pharmacia LKB Biotechnology AB (Uppsala, Sweden). A Phenyl-5PW column was purchased from Tosoh (Tokyo, Japan). A Centricon YM10 centrifuge was purchased from Millipore (Bedford, MA, USA). Porcine pancreatic PLA 2 was purchased from Sigma Chemical Co. (St Louis, MO, USA). cPLA 2 a was purified from porcine spleen as described previously (31) . Rat platelet group II PLA 2 was partially purified from rat platelets as described previously (32) .
Anti-cPLA 2 antibody was prepared as described previously (31 C]AA-GPE, was dried under nitrogen and resuspended in ethanol. The standard incubation system (100 ml) for assay of cPLA 2 activity contained the cPLA 2 preparation, 75 mM TrisHCl at pH 7.5, 5 mM CaCl 2 and 4.5 nmol of the substrate ($55,000 cpm). iPLA 2 activity assay was performed in the standard reaction buffer (100 ml) contained iPLA 2 preparations, 200 mM TrisHCl, pH 7.5, 5 mM EDTA and 4.5 nmol of the substrate. The reactions were carried out at 37 C for 5 min and stopped by adding 560 ml of modified Dole's reagent (n-heptane/isopropyl alcohol/1 N-H 2 SO 4 ; 400/390/10, by volume) (33) and 110 ml of water, vortex mixed and centrifuged. Then, 150 ml of the upper phase was transferred to a new microtube, to which 800 ml of n-heptane and silica gel ($5 mg) was added. The sample was vortex mixed and centrifuged again and an aliquot (800 ml) of the supernatant was removed and added to 2.5 ml of b-scintillation solution (INSTA GEL-XF) and counted for radioactivity with a Packard Tri-Carb liquid scintillation counter (Packard Instrument Co, Meriden, CT, USA). In order to characterize GTP effect, cPLA 2 activity was assayed in the presence of 2.5 mM of MgCl 2 . The cPLA 2 activity itself was not affected by Mg 2þ . To measure cPLAP activity, an aliquot of the sample preparation was added to the assay system for cPLA 2 activity and expressed as an n-fold increase in activity.
Detection and purification of cPLAPc and iPLA 2 Bovine brain was freshly obtained from a local slaughterhouse and frozen at À70 C. A 600g portion of brain was thawed in five volumes of homogenizing buffer V (50 mM TrisHCl at pH 7.5, 50 mM KCl, 3 mM MgCl 2 , 1 mM EDTA and 10 mM 2-mercaptoethanol) with a Polytron PT-MR6000 (Kinematica AG, Rittau, Switzerland). The homogenates were centrifuged at 10,000g for 60 min. The resulting supernatants were adjusted to pH 5.0 with acetic acid and centrifuged again at 10,000g for 15 min. After centrifugation, precipitates were resuspended in buffer V using Polytron at 4
C. The resuspension of pH 5.0-precipitate was loaded onto a DEAE-cellulose anion exchange column (DE52, 2.5 mm Â 12.5 cm, bed volume 200 ml; Whatman Ltd) designed for use with a P-3 peristaltic pump (Pharmacia LKB Biotechnology AB) with buffer A (50 mM TrisHCl at pH 7.5, 1 mM EDTA and 10 mM 2-mercaptoethanol) at a flow rate of $25 ml/min, and the column was washed with buffer A. The washed column was eluted at a flow rate of 25 ml/min with a stepwise gradient of 01.0 M NaCl. The protein fractions eluted with 1.0 M NaCl were fractionated at 30 ml per fraction. A 20-ml aliquot of each fraction was assayed for iPLA 2 and cPLA 2 -activating activities. The active fractions with iPLA 2 activity were pooled.
The active fractions from the DEAE-cellulose column were pooled and adjusted to 0.5 M (NH 4 ) 2 SO 4 by adding 4.0 M (NH 4 ) 2 SO 4 solution and applied to a Phenyl-Sepharose CL-4B column (30 mm Â 25 cm, bed volume 30 ml; Pharmacia LKB Biotechnology) pre-equilibrated with buffer A containing 0.5 M (NH 4 ) 2 SO 4 . The column was eluted at a flow rate of 10 ml/min with sequential stepwise elution of buffer A containing 0.25 M (NH 4 ) 2 SO 4 and buffer B (25 mM glycineNaOH at pH 9.0, 1 mM EDTA, and 10 mM 2-mercaptoethanol). A 20-ml aliquot of each 10 ml fraction was assayed for iPLA 2 and cPLA 2 -activating activities at 37 C for 5 min. The active pool of the Phenyl-Sepharose CL-4B column was adjusted to 0.75 M (NH 4 ) 2 SO 4 and applied to Phenyl-5PW HPLC column, which was pre-equilibrated with buffer A containing 0.75 M (NH 4 ) 2 SO 4 . The column was eluted at a flow rate of 5 ml/min with a linear gradient with water. The active fractions with cPLA 2 -activating activity were pooled, dialyzed with buffer S (25 mM imidazoleHCl at pH 6.6, 3 mM MgCl 2 , 1 mM EDTA and 10 mM 2-mercaptoethanol) for 18 h. The dialyzed sample was applied to a Resource S FPLC column (1 ml; Pharmacia LKB Biotechnology AB) pre-equilibrated with buffer S. The column was eluted at a flow rate of 1 ml/min with a linear gradient of 0.01.0 M NaCl. A 20-ml aliquot of each 1 ml fraction was assayed for cPLA 2 -activating activity. The active fractions ($3.0 ml) were concentrated to 400 ml using a Centricon YM10 (Millipore). The active concentrate was applied to a Superose 12 gel filtration FPLC column (Pharmacia LKB Biotechnology AB) pre-equilibrated with buffer G (50 mM TrisHCl at pH 7.5, 1 mM EDTA, 10 mM 2-mercaptoethanol and 0.1 M NaCl). The column was eluted at a flow rate of 0.5 ml/min. A 50-ml aliquot of each 0.5 ml fraction was assayed for cPLA 2 -activating activity at 37 C for 5 min. The 42-kDa peak fractions were pooled and dialyzed with buffer S (25 mM imidazole/HCl at pH 6.6, 3 mM MgCl 2 , 1 mM EDTA and 10 mM 2-mercaptoethanol) for 18 h. The dialyzed sample was applied to a Mono S FPLC column (1 ml/bed volume; Pharmacia LKB Biotechnology AB) pre-equilibrated with buffer S. The column was eluted at a flow rate of 1 ml/min with a linear gradient of 0.01.0 M NaCl. A 20-ml aliquot of each 1.0 ml fraction was assayed for cPLA 2 -activating activity.
Photoaffinity labelling of cPLAPc with [a- 32 
P]GTP
To determine whether GTP binds to cPLAPg by photoreaction, photoaffinity labelling of cPLAPg with [a-32 P]GTP was performed as previously described (34, 35) with a minor modification. Briefly, the samples were mixed with 510 mCi of [a-32 P]GTP, 0.1 mM AppNHp and 2 mM MgCl 2 and pre-incubated for 5 min at 4 C. The samples were then placed in an ice bath and irradiated with UV light (254 nm) for 510 min using a UV cross-linker (SPECTROLINKER XL-1000, Spectronics Co, Manukau City, New Zealand). After irradiation, the samples were mixed with Laemmli's stopping solution (36) and allowed to stand at room temperature for 1 h. The samples were subjected to SDSPAGE using 812% gels, and the gels were dried and exposed overnight on Kodak X-OMAT XAR-5 film using DuPont image intensifying screens.
Co-immunoprecipitation of cPLAPc with cPLA 2 in HL60 and U937 cells metabolically labelled with L-[
S]methionine
The cells cultured in DMEM (10% FCS) were collected by centrifugation at 400g for 5 min. The resulting pellets were resuspended in DMEM (10% FCS) without L-methionine supplemented with L-glutamine (2%) as a wash buffer and centrifuged at 400g at room temperature for 5 min. After removing the wash buffer as completely as possible, the cells were resuspended in methionine-free medium (1 Â 10 7 cells/ml). After transferring to a small tissue culture plate (16 mm, 24 wells/plate), the cells were incubated for 30 min at 37 C to exhaust the remaining methionine.
Then 100 mCi [ 35 S]methionine was added to the plates and the cells were allowed to incorporate the radiolabel into total protein for 3 h. The cells were treated with 1 mM A23187 for 30 min, transferred to a test tube and washed twice with PBS. The resulting pellets were resuspended in 1 ml of a RIPA buffer (150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM TrisHCl at pH 7.5 and 1 mM EDTA) per 1Â 10 7 cells for lysis. The cells were kept on ice for 30 min with occasional mixing and spun down for 10 min at 10,000g at 4 C. The resulting supernatants were centrifuged at 100,000g for 30 min and the supernatants used as the soluble cell-free fractions.
To pre-clear proteins in the soluble fractions that bind non-specifically to immune complexes or the solid phase, 1 ml fractions were incubated with 50 ml of normal serum on ice for 1 h. Then 500 ml of 10% washed suspension of fixed Staphylococcus aureus Cowan I (SAC) was added to the lysates and further incubated for 30 min on ice. The resulting supernatants were incubated with 20 ml of anti-cPLA 2 antibody bound to Protein A-Sepharose beads for 12 h. Immune complexes bound to the beads were pelleted at 1,000g at 4 C for 3 min and washed five times with 1 ml of the lysis buffer. The cPLA 2 and associated proteins were eluted by incubating for 5 min at 100 C with 70 ml of 2Â Laemmli's buffer and subjected to 10% SDSPAGE. After washing twice for 30 min with DMSO, the gel was reacted with 22% PPO in DMSO for 1 h and extensively washed for 30 min with water in a circulating chamber. Then, the gel was dried at 80 C for 40 min and exposed to film overnight at À70 C for fluorography.
Results
Detection and partial purification of cPLAPc Recently, we identified and purified a novel form of iPLA 2 in the pH 5.0-precipitate of the brain homogenate (Eui Man Jeong et al., manuscript in preparation). The brain homogenates were resuspended with buffer V and applied to a DEAE-cellulose anion exchange column, where the iPLA 2 activity was eluted with a stepwise gradient of 1.0 M NaCl with an 82% yield and $10.5-fold purification (Fig. 1A) . The active fractions of iPLA 2 were adjusted to 0.5 M (NH 4 ) 2 SO 4 and then applied to a Phenyl-Sepharose CL-4B hydrophobic column. The bound proteins were eluted with stepwise gradients of buffer A containing 0.25 M (NH 4 ) 2 SO 4 and buffer B containing no salt, respectively. The iPLA 2 activity was eluted in the glycine-eluted fractions with a yield of 520%, but not in 0.25 M (NH 4 ) 2 SO 4 elution (Fig. 1B) . This low yield prompted us to examine an existence of an activator in other fractions. First, we observed a small increase by $1.21.5-fold in iPLA 2 activity in the 0.25 M (NH 4 ) 2 SO 4 -elution fractions, but this result could not explain the low yield in this step (data not shown). Since we cannot exclude the possible existence of cPLA 2 in the glycine-eluted fraction, we added a highly purified cPLA 2 from porcine spleen to the 0.25 M (NH 4 ) 2 SO 4 -elution fractions. Interestingly, as shown in Figure 1B , a significant cPLA 2 -activating activity was observed in the 0.25 M (NH 4 ) 2 SO 4 -elution fractions. One unit of cPLA 2 -activating activity was defined as the ability that doubles 52 nmol/min of the total activity of the purified spleen cPLA 2 for 5 min/mg of each protein in the samples. For purification, the fractions showing cPLA 2 -activating activity were readjusted to 0.75 M (NH 4 ) 2 SO 4 and then applied to a Phenyl-5PW HPLC column (Fig. 1C) . The active fractions were pooled and dialyzed for 18 h. Then, the dialyzed sample was applied to a Resource S FPLC column (Fig. 1D ). The active fractions had 55% less protein and a total activity recovery of $60% compared with the loaded sample. Finally, a 3.0-ml pool of the active fractions from the Resource S FPLC column was concentrated to $400 ml and applied to a Superose 12 gel filtration FPLC column. The cPLA 2 -activating activity was separated into two major peaks of apparent molecular masses of 200 and 42 kDa, termed peak a and g, respectively (Fig. 1E) . The 42-kDa protein of peak g was further purified using a Mono S cation exchange FPLC column (Fig. 1F) . The column was eluted with a sequential stepwise elution and each fraction was assayed for cPLAP activity as described in 'Materials and Methods' section. The iPLA 2 activity was eluted in the elution step without salt. (C) Phenyl-5PW HPLC column profile of cPLAP. The pool of the active cPLAP fractions of the Phenyl-Sepharose CL-4B column was applied to a Phenyl-5PW HPLC column pre-equilibrated with buffer A. The column was eluted and each fraction was assayed for cPLAP activity as described in 'Materials and Methods' section. (D) Resource S FPLC profile of the active pool from the Phenyl-5PW column. The active pool was dialyzed and applied to a Resource S FPLC column pre-equilibrated with buffer S. The column was eluted and assayed for cPLAP activity as described in 'Materials and Methods' section. Fraction numbers 5961 were pooled for the next step. (E) Superose 12-gel filtration FPLC profile of cPLAP. The active pool of Resource S was applied to a Superose 12 FPLC column pre-equilibrated with buffer T. The column was eluted and assayed for cPLAP activity as described in 'Materials and Methods' section. (F) Mono S cation exchange FPLC profile of cPLAP. The active pool of Superose 12 FPLC column was applied to a Mono S FPLC column, which was eluted and assayed for cPLAP activity as described in 'Materials and Methods' section.
Effects of cPLAPc on various types of PLA 2 A 20-ml aliquot of the active pool obtained from the Mono S FPLC column was assayed for cPLAP activity. To examine the substrate specificity of the acyl chains at the sn-2 position, PLA 2 -activating activity was assayed for 2-PA-PC, 2-LA-PC and 2-AA-PC. There was no preferential activity of cPLA 2 toward AA at the sn-2 position (Figure 2A ). The effects of cPLAPg on various types of PLA 2 were then examined. cPLAPg enhanced group IVA PLA 2 activity by $2-fold, but did not affect pancreatic group I, non-pancreatic group II or partially purified iPLA 2 from the bovine brain. The results indicate that cPLAPg activated significantly cPLA 2 by up to $2.5-fold ( Figure 2B ). Next, we also examined the effects of GTPgS on cPLAPg activity. The addition of GTPgS further increased the activating effect of cPLAPg on cPLA 2 a (Figure 2A and B) . The data suggest that cPLAPg may be a GTP-binding protein.
To determine the nature of the cPLA 2 -activating activity, the effects of boiling and digestion with trypsin on cPLA 2 -activating activity were assessed ( Figure 2C) . A 20-ml aliquot of the active fractions from Mono S was pre-incubated for 15 and 30 min at 75 C, followed by 0.5 mg/ml of trypsin and then the trypsin inhibitor 0.25 mg/ml aprotinin, or vice versa, before addition of the cPLA 2 enzyme source. The cPLA 2 -activating activity was sensitive to boiling and digestion with trypsin, thus the cPLA 2 -activating activity is attributable to a protein in the preparation, and is named cPLA 2 -activating protein accordingly.
cPLAPc has characteristics of G protein To characterize the cPLAPg, the effects of guanine nucleotides on the activity of cPLAP were investigated. Because most of the GTP proteins require an appropriate concentration of Mg 2þ for nucleotide binding Identification of cPLA 2 -activating protein as a G protein and configuration, 2.5 mM of MgCl 2 was added to the standard assay system. The cPLA 2 activity itself was not affected by Mg 2þ (data not shown). As shown in Figure 3A , cPLAP activity enhanced by GTPgS required the presence of Mg 2þ . ATP and AppNHp, other purine nucleotides whose structures are similar to the guanine nucleotide, had no effect ( Figure 3A) . GTPgS dose-dependently enhanced cPLAPg activity up to $1.5-to 2.0-fold, whereas GDPbS, a non-hydrolyzable GDP analogue, dose-dependently decreased the enhanced cPLAPg activity ( Figure 3B ). To further confirm the possibility that cPLAPg may be a G protein, a photoaffinity labelling experiment with [a-32 P]GTP was performed ( Figure 3C ). When the active fractions from Resource S and Superose 12 columns were labelled with [a-32 P]GTP, proteins with molecular masses of 42 and 52 kDa were cross-linked with UV and the protein band at 42 kDa was seen at the same position as the major band from the Mono S column of the final step ( Figure 3C ). Furthermore, cPLAPg was observed as a 42 kDa band, paralleled with the activity from the Mono S column ( Figure 3D ). These results strongly suggest that cPLAPg may be a GTP-binding protein. The cPLAP activity appearing with $200 kDa molecular mass in the Superose 12 gel filtration FPLC was not affected by guanine nucleotides nor was labelled by UV cross-linking (data not shown). Figure 4 , Protein A-Sepharose beads bound to anti-cPLA 2 antibody precipitated a 42-kDa protein from both HL60 and U937 cells, but those bound to normal serum did not.
On the other hand, it is important whether interaction of cPLA 2 and cPLAPg require an increase in intracellular Ca 2þ concentration. Our results showed that proteins from A23187-untreated cell had no different effect on the interaction of cPLAPg toward cPLA 2 (data not shown). Although intracellular Ca 2þ is not required to interaction between cPLAPg and cPLA 2 , there is a possibility that cPLAPg could make cPLA 2 more active through increase of Ca 2þ sensitivity. Next, we investigated the effects of Ca 2þ on the increase of cPLA 2 activity by cPLAPg.
Ca 2þ
-dependency of the cPLA 2 -activating activity of cPLAPc cPLA 2 is known to have full activity at a micromolar concentration of Ca 2þ . Interestingly, the present data indicate that cPLAPg fully activates cPLA 2 even at sub-micromolar concentrations of Ca 2þ ( Figure 5 ). The effect of GTPgS on the activity of cPLAPg may be due to its ability to enhance cPLAPg activity rather than to increase its sensitivity to submicromolar Ca was also inhibited by GDPbS in a dose-dependent manner (data not shown).
Discussion
AA is known to serve as a chemical mediator as well as a second messenger and is generated in membrane lipids by activation of cPLA 2 (1, 2). The cPLA 2 enzyme is strictly regulated and abnormal signalling is believed to cause serious pathological disasters. The regulatory mechanisms of cPLA 2 have been extensively studied to understand the nature of its pathogenesis and to develop new therapy targets. However, the mechanism by which AA is released at an early stage of stimulation remains largely unknown.
G proteins have been proposed as a transducer and molecular switch for cPLA 2 . Many phospholipases have been shown to be regulated by directly interacting with specific G proteins (1618). There have been many attempts to discover a corresponding G protein that regulates cPLA 2 (24) . Several lines of evidence are accumulating that AA release in various cells and tissues is regulated by G proteins using guanine nucleotide analogues and bacterial toxins such as cholera and pertussis toxin (25) . It has also been suggested that a Rac1 G protein may serve as a mediator of cPLA 2 activation (27, 28) . However, at present, there is no direct evidence for the existence of a G protein coupled with cPLA 2 either in vivo or in vitro.
The present study reports a G protein that may interact with cPLA 2 to mediate its activation based on the following results: (i) cPLAPg selectively increased cPLA 2 activity among various mammalian types of PLA 2 ; (ii) cPLAPg activity was enhanced by GTPgS and decreased by GDPbS in a dose-dependent manner, and this effect required Mg 2þ ; (iii) ATP and other purine nucleotides such as AppNHp had no effect under the same conditions; (iv) cPLAPg was ]-methionine and treated with 1 mM A23187 as described in 'Materials and Methods' section. The cells were resuspended in an RIPA buffer containing 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS and 1 mM EDTA for lysis and spun down to obtain the resulting supernatants, as described in 'Materials and Methods' section. The proteins of the soluble fractions were pre-cleared and incubated with anti-cPLA 2 antibody bound to Protein A-Sepharose beads. The cPLA 2 and associated proteins in the immune complexes were eluted and subjected to 10% SDSPAGE as described in 'Materials and Methods' section. The gel was then dried at 80 C for 40 min and exposed to film overnight at 70 C for fluorography. Two major peaks associated with cPLAP activity were detected, peaks a and g, from the Superose 12-gel filtration FPLC column ( Figure 1E ). Peak a of $200 kDa was not responsive to GTPgS or GDPbS (data not shown). Peak g, termed cPLAPg, was further purified with a Mono S cation exchange FPLC column to near homogeneity ( Figure 1F ). Based on SDSPAGE analysis, photoaffinity labelling of cPLAPg, and the migration profile in gel filtration chromatography, the molecular weight of cPLAPg was estimated 42 kDa. Because the molecular mass of the a-subunit of the heterotrimeric G protein is 42 kDa and AlF4
À is an activator of the a-subunit, the effect of AlF4 À on the cPLAPg activity was examined. Unfortunately, the effect could not be evaluated because AlF4
À significantly inhibited cPLA 2 activity in a dose-dependent manner (data not shown). Thus the cross-reactivity with antibodies against previously known six types of G proteins, Gs, Gi, Gq, Go, Gi 2 and Gi 3 proteins, was also examined through the immunoblot analysis on fraction of final purification step, but the 42 kDa cPLAPg did not react with any of them (data not shown).
Further study should also be carried out to examine whether the 42-kDa band as shown by fluorography in Figure 4 is cPLAPg. Metabolic labelling analysis suggested that cPLAPg may associate with cPLA 2 . However, neither cPLA 2 activity nor cPLAPg activity was detected in the immunoprecipitates obtained from the metabolic labelling cells (data not shown), suggesting that the RIPA buffer may denature the proteins, with consequent loss of their activities. The authors' previous study showed that considerable cPLA 2 activity was detected in immunoprecipitates obtained using an anti-cPLA 2 antibody (31).
In the rat brain, cPLA 2 was ubiquitously expressed throughout the brain (37) . Although cPLA 2 activity comprises a small amount of the total PLA 2 activity of the brain tissue, its specific activity is high. Such a small amount of cPLA 2 activity may have important biological and pathological functions (38) . cPLA 2 is functionally linked with both COX-1 and COX-2 during immediate and delayed eicosanoid production (39) . Coordinated up-regulation of cPLA 2 and COX-2 activities is also thought to contribute to brain damage following cerebral ischaemia and neuroinflammation (40) . On the other hand, it was demonstrated that PLA 2 activating proteins occur in Aplysia neurons and rat cerebral cortex (41). In the context of our results and previous reports, we hypothesize that cPLAPg is important in cPLA 2 regulation and may be involved in inflammatory response induced by G protein coupled receptors. G protein coupled receptors in the brain may activate cPLAPg, in turn, trigger increase of cPLA 2 activity that results in neuronal apoptosis or pathological changes. Although this is an appealing possibility, we do not currently have data to support this. Further study should also be carried out to identify and elucidate its primary structure and more precise mechanism for the cPLA 2 activation.
On the other hand, cPLA 2 activity is known to be regulated by the intracellular concentration of Ca 2þ (9, 42) . Activity was not detected at concentrations of 1 to 5 Â 10 À7 M Ca 2þ observed in the resting cells, but cPLA 2 was fully activated at a concentration of $10 À6 M Ca 2þ enhanced by stimulation (9, 42) . Interestingly, cPLAPg fully activated cPLA 2 at sub-micromolar concentration of Ca 2þ ( Figure 5 ), suggesting that cPLA 2 may become sensitive to lower concentrations of Ca 2þ through cPLAPg activity. This finding strongly supports the possibility that cPLA 2 may be activated irrespective of the PI-PLC pathway, which is known to be activated through G protein-coupled receptor activation to produce IP 3 and DAG (43) . It has been unclear whether cPLA 2 activation is dependent on the activation of PI-PLC, which could trigger a sharp increase in intracellular Ca 2þ via the role of IP 3 in Ca 2þ mobilization (44) . Many lines of evidence indicate that the release of AA from membrane lipids could occur without the generation of IP 3 (45) , suggesting activation of PLA 2 prior to activation of PI-PLC. However, no evidence has been provided to explain this phenomenon. The present results may shed light on this longstanding and controversial finding that cPLA 2 can be activated without the involvement of PI-PLC (46, 47) .
At present, the biochemical mechanism by which cPLAPg enhances cPLA 2 activity and allows the enzyme to fully activate at sub-micromolar concentrations of Ca 2þ remains unknown. It has been reported that cPLA 2 contains a pleckstrin homology (PH) domain and interacts with multi-modular membrane-binding proteins that play key roles in signal transduction (8) . The PH domain is known as a site of action for certain G proteins, and thus may be a site of action for cPLAPg.
In summary, cPLAPg was identified as a 42-kDa G protein that specifically enhances the in vitro activity of cPLA 2 . cPLAPg associates with cPLA 2 and allows the enzyme to fully activate at sub-micromolar concentrations of Ca 2þ . In addition, cPLAPg is suggested to play a role in the release of AA by activating cPLA 2 at an early stage prior to activation of PI-PLC, which is known to provide the micromolar concentrations of Ca 2þ required for full activation of cPLA 2 . To verify this, the precise nature of cPLAPg should be dissected through sequencing of its primary structure and a study of the interaction between cPLAPg and cPLA 2 . 
